{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:53:03Z","timestamp":1790617983170,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41433-021-01778-6","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T11:58:59Z","timestamp":1632830339000},"page":"1945-1950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Type one macular neovascularization in central serous chorioretinopathy: Short-term response to anti-vascular endothelial growth factor therapy"],"prefix":"10.1038","volume":"36","author":[{"given":"Rapha\u00ebl","family":"Lejoyeux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Behar-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-8194","authenticated-orcid":false,"given":"Irmela","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1105-9265","authenticated-orcid":false,"given":"Jorge","family":"Ruiz-Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mrejen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Tadayoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gaudric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-1385","authenticated-orcid":false,"given":"Elodie","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"1778_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015;48:82\u2013118.","journal-title":"Prog Retin Eye Res"},{"key":"1778_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00006982-199414030-00008","volume":"14","author":"FC Piccolino","year":"1994","unstructured":"Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retin (Phila, Pa). 1994;14:231\u201342.","journal-title":"Retin (Phila, Pa)"},{"key":"1778_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1097\/IAE.0b013e3181be0a83","volume":"29","author":"Y Imamura","year":"2009","unstructured":"Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retin (Phila, Pa). 2009;29:1469\u201373.","journal-title":"Retin (Phila, Pa)"},{"key":"1778_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33:14\u201333.","journal-title":"Eye (Lond)"},{"key":"1778_CR5","first-page":"1013","volume":"3","author":"J Siedlecki","year":"2019","unstructured":"Siedlecki J, Schworm B, Priglinger SG. The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol. Retina 2019;3:1013\u20135.","journal-title":"Retina"},{"key":"1778_CR6","doi-asserted-by":"crossref","unstructured":"Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina (Philadelphia, Pa). 2018;38:629\u201338.","DOI":"10.1097\/IAE.0000000000001580"},{"key":"1778_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ajo.2015.08.028","volume":"160","author":"KK Dansingani","year":"2015","unstructured":"Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol. 2015;160:1243\u201354.","journal-title":"Am J Ophthalmol"},{"key":"1778_CR8","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1432\u201344.","journal-title":"N. Engl J Med"},{"key":"1778_CR9","doi-asserted-by":"crossref","unstructured":"Brown D, Michels M, Kaiser P, Heier J, Sy J, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR Study [Internet]. Vol. 116, Ophthalmology. Ophthalmology; 2009 [cited 2020 Jun 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19118696\/?from_term=brown+anchor+2009&from_pos=1","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"1778_CR10","doi-asserted-by":"crossref","unstructured":"Tufail A, Narendran V, Patel P, Sivaprasad S, Amoaku W, Ac B, et al. Ranibizumab in myopic choroidal neovascularization: The 12-month results from the REPAIR study [Internet]. Vol. 120, Ophthalmology. Ophthalmology; 2013 [cited 2020 Jun 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24001532\/?from_term=tufail+myopia+&from_pos=10","DOI":"10.1016\/j.ophtha.2013.06.010"},{"key":"1778_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1038\/s41433-019-0511-2","volume":"33","author":"R Sacconi","year":"2019","unstructured":"Sacconi R, Tomasso L, Corbelli E, Carnevali A, Querques L, Casati S, et al. Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study. Eye (Lond). 2019;33:1809\u201317.","journal-title":"Eye (Lond)"},{"key":"1778_CR12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00417-020-04623-w","volume":"258","author":"B Schworm","year":"2020","unstructured":"Schworm B, Luft N, Keidel LF, Hagenau F, Kern C, Herold T, et al. Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. Graefes Arch Clin Exp Ophthalmol. 2020;258:1013\u201321.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1778_CR13","doi-asserted-by":"crossref","unstructured":"Romdhane K, Zola M, Matet A, Daruich A, Elalouf M, Behar-Cohen F, et al. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. Br J Ophthalmol. 2020;104:910\u201316.","DOI":"10.1136\/bjophthalmol-2019-314625"},{"key":"1778_CR14","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/IAE.0000000000001744","volume":"38","author":"TYY Lai","year":"2018","unstructured":"Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: Twelve-month results of the MINERVA Study. Retin (Phila, Pa). 2018;38:1464\u201377.","journal-title":"Retin (Phila, Pa)"},{"key":"1778_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/eye.2016.41","volume":"30","author":"E Smretschnig","year":"2016","unstructured":"Smretschnig E, Hagen S, Glittenberg C, Ristl R, Krebs I, Binder S, et al. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye (Lond). 2016;30:805\u201311.","journal-title":"Eye (Lond)"},{"key":"1778_CR16","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","volume":"35","author":"E Bousquet","year":"2015","unstructured":"Bousquet E, Beydoun T, Rothschild P-R, Bergin C, Zhao M, Batista R, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retin (Phila, Pa). 2015;35:2505\u201315.","journal-title":"Retin (Phila, Pa)"},{"key":"1778_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2018.06.009","volume":"193","author":"C Shiragami","year":"2018","unstructured":"Shiragami C, Takasago Y, Osaka R, Kobayashi M, Ono A, Yamashita A, et al. Clinical features of central serous chorioretinopathy with type 1 choroidal neovascularization. Am J Ophthalmol. 2018;193:80\u20136.","journal-title":"Am J Ophthalmol"},{"key":"1778_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","volume":"126","author":"S Mrejen","year":"2019","unstructured":"Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, et al. Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology 2019;126:576\u201388.","journal-title":"Ophthalmology"},{"key":"1778_CR19","doi-asserted-by":"crossref","unstructured":"Chen Y-C, Chen S-N Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy. Br J Ophthalmol. 2020;104:1561\u201366.","DOI":"10.1136\/bjophthalmol-2019-315302"},{"key":"1778_CR20","doi-asserted-by":"crossref","unstructured":"Romano MR, Parolini B, Allegrini D, Mickalewska Z, Adelman R, Bonovas S, et al. An international collaborative evaluation of central serous chorioretinopathy: Different therapeutic approaches and review of literature. The European vitreoretinal society central serous chorioretinopathy study. Acta Ophthalmol. 2019;06.","DOI":"10.1111\/aos.14319"},{"key":"1778_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11096-017-0460-4","volume":"39","author":"S Ji","year":"2017","unstructured":"Ji S, Wei Y, Chen J, Tang S. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: A meta-analysis. Int J Clin Pharm. 2017;39:514\u201321.","journal-title":"Int J Clin Pharm"},{"key":"1778_CR22","doi-asserted-by":"publisher","first-page":"e0248760","DOI":"10.1371\/journal.pone.0248760","volume":"16","author":"A Miki","year":"2021","unstructured":"Miki A, Kusuhara S, Otsuji T, Kawashima Y, Miki K, Imai H, et al. Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS One. 2021;16:e0248760.","journal-title":"PLoS One"},{"key":"1778_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archopht.1991.01080050091036","volume":"109","author":"JD Gass","year":"1991","unstructured":"Gass JD. Central serous chorioretinopathy and white subretinal exudation during pregnancy. Arch Ophthalmol. 1991;109:677\u201381.","journal-title":"Arch Ophthalmol"},{"key":"1778_CR24","doi-asserted-by":"crossref","unstructured":"Bouzas E, Karadimas P, Pournaras C Central Serous Chorioretinopathy and Glucocorticoids [Internet]. Vol. 47, Survey of ophthalmology. Surv Ophthalmol; 2002 [cited 2020 Jun 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12431693\/?from_term=bouzas+2002&from_pos=1","DOI":"10.1016\/S0039-6257(02)00338-7"},{"key":"1778_CR25","doi-asserted-by":"crossref","unstructured":"Nair U, Ganekal S, Soman M, Nair K Correlation of spectral domain optical coherence tomography findings in acute central serous chorioretinopathy with visual acuity [Internet]. Vol. 6, Clinical ophthalmology (Auckland, N.Z.). Clin Ophthalmol; 2012 [cited 2020 Jun 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23225998\/?from_term=nair+fibrin+2012&from_pos=6","DOI":"10.2147\/OPTH.S38363"},{"key":"1778_CR26","doi-asserted-by":"crossref","unstructured":"Yannuzzi N, Mrejen S, Capuano V, Bhavsar K, Querques G, Freund K A Central hyporeflective subretinal lucency correlates with a region of focal leakage on fluorescein angiography in eyes with central serous chorioretinopathy [Internet]. Vol. 46, Ophthalmic surgery, lasers & imaging retina. Ophthalmic Surg Lasers Imaging Retina; 2015 [cited 2020 Jun 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26431298\/?from_term=Yannuzzi+2015&from_page=3&from_pos=7","DOI":"10.3928\/23258160-20150909-07"},{"key":"1778_CR27","doi-asserted-by":"crossref","unstructured":"Maruko I, Iida T, Ojima A, Sekiryu T Subretinal dot-like precipitates and yellow material in central serous chorioretinopathy [Internet]. Vol. 31, Retina (Philadelphia, Pa.). Retina; 2011 [cited 2020 Jun 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21052035\/?from_term=maruko+2011&from_pos=2","DOI":"10.1097\/IAE.0b013e3181fbce8e"},{"key":"1778_CR28","doi-asserted-by":"crossref","unstructured":"Shah V, Shah S, Mrejen S, Freund K Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration [Internet]. Vol. 34, Retina (Philadelphia, Pa.). Retina; 2014 [cited 2020 Jun 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24695062\/?from_term=subretinal+hyperreflective+material+shah&from_pos=1","DOI":"10.1097\/IAE.0000000000000166"},{"key":"1778_CR29","doi-asserted-by":"crossref","unstructured":"Behar-Cohen F, Dernigoghossian M, Andrieu-Soler C, Levy R, Cohen R, Zhao M Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization. Drug Discov Today. 2019;24:1436\u201339.","DOI":"10.1016\/j.drudis.2019.05.034"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01778-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01778-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01778-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T11:31:34Z","timestamp":1699529494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01778-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1778"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01778-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}